A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Active, not recruiting · Phase 2 · NCT06037252
Conditions: Type 2 Diabetes, Obesity
At a glance
- Research payments reported, 2025
- $2.8M
- U.S. investigators named
- 25
- Sites paid
- 21
- Planned or actual enrollment
- 414
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Placebo (drug)
- Dates
- Started 2023-09-21; completion 2026-10
- Results posted
- Not yet
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
From ClinicalTrials.gov, last updated 2026-03-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2.8M in research payments for this study in 2025 (49 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jitendra Sharma, M.B.B.S Neurology · Birmingham, AL
- Jeffrey R. Hoodin, M.D. Internal Medicine · Tempe, AZ
- Anna R. Chang, M.D. Internal Medicine · Concord, CA
- Francisco L. Garcia, M.D. Family Medicine · Sacramento, CA
- Mauricio L. Waintrub, M.D. Internal Medicine · Aurora, CO
- Joseph Soufer, M.D. Internal Medicine · Waterbury, CT
- Luis Del Prado, MD Family Medicine · Miami, FL
- Pedro Gonzalez Amaro, MD General Practice · Homestead, FL
- Vasundhara Cheekati, M.D. Hospitalist · Lawrenceville, GA
- Alan B. Miller, M.D. Internal Medicine · Peachtree Corners, GA
- James A. Coggi, M.D. Pediatrics · West Des Moines, IA
- Thomas J. Schnitzer, MD, PHD Sports Medicine · Chicago, IL
- David E. Schultz II, M.D. Family Medicine · Evansville, IN
- Matthew D. Wenker, MD Internal Medicine · Erlanger, KY
- John C. Parker, M.D. Endocrinology & Diabetes · Wilmington, NC
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Agam Bansal, MD Internal Medicine · Cleveland, OH
- Robert E. Dunn, MD Cardiac Electrophysiology · Cleveland, OH
- Beal Essink, MD Psychiatry · Salem, OR
- Stephan C. Sharp, MD Endocrinology & Diabetes · Nashville, TN
- Sumana Gangi, M.D Endocrinology & Diabetes · Mesquite, TX
- Damaris Vega, MD Endocrinology & Diabetes · Houston, TX
- James R. Clark, MD Internal Medicine · Charlottesville, VA
- Gaylon Kipp, MD Family Medicine · Bellevue, WA
- Nazia H. Rahman, M.D. Pediatrics · Bellevue, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Retreat Medical Research LLC $707,166
- Alan B Miller MD DBA Alta Pharmaceutical Research $618,898
- Agile Clinical Research Trials $255,955
- Medical Advancement Centers of Arizona LLC $214,129
- American Research Centers $212,138
- Northwestern University $114,310
- Juno Research LLC $108,696
- Summit Headlands LLC $98,240
- Care Access Research LLC $86,857
- John Muir Med Fndtn DBA John Muir Phys Network $79,782
- Qualmedica Research LLC $71,891
- Southern Endocrinology Associates PA $69,911
- Clinical Research Associates Inc $44,165
- Piedmont Medical Research Associates Inc $39,874
- Chase Medical Research LLC $34,683
- Northwest Clinical Research Center $31,019
- $22,554
- Clark Medical Research LLC $9,745
- Integrated Clinical Trial Services Inc $7,203
- American Health Network of in LLC $5,747
- Velocity Clinical Research Inc $2,099
- Cleveland Clinic, OH $248
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.